Patents by Inventor THOMAS E. JANUARIO

THOMAS E. JANUARIO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for diagnosing and treating cancer
    Patent number: 11261498
    Abstract: The present invention provides methods of treating cancer based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of administering an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Thomas E. Januario, David Shames
  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    Publication number: 20210338684
    Abstract: The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SMARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).
    Type: Application
    Filed: July 8, 2021
    Publication date: November 4, 2021
    Inventors: Robert L. YAUCH, Xiaofen YE, Thomas E. JANUARIO
  • DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
    Publication number: 20200129519
    Abstract: The present invention provides diagnostic and therapeutic methods for cancer. The invention provides methods of determining whether a patient having a cancer is likely to respond to treatment comprising an inhibitor of H3K27 methylation, methods of predicting responsiveness of a patient having a cancer to treatment comprising one or more inhibitors of H3K27 methylation, methods of selecting a therapy for a patient having a cancer, and methods of treating cancer based on expression levels of biomarkers of the invention (e.g., the expression level of SIV1ARCA2 or the occupancy level of H3K27 at a SMARCA2 promoter).
    Type: Application
    Filed: June 8, 2017
    Publication date: April 30, 2020
    Applicants: Genentech, Inc., Genentech, Inc.
    Inventors: Robert L. YAUCH, Xiaofen YE, Thomas E. JANUARIO
  • DIAGNOSTIC MARKERS
    Publication number: 20200024670
    Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Application
    Filed: October 2, 2019
    Publication date: January 23, 2020
    Applicant: Genentech, Inc.
    Inventors: Thomas E. Januario, David Shames
  • DIAGNOSTIC MARKERS
    Publication number: 20170306419
    Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 26, 2017
    Applicant: Genentech, Inc.
    Inventors: Thomas E. Januario, David Shames
  • DIAGNOTIC MARKERS
    Publication number: 20150086543
    Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Application
    Filed: November 24, 2014
    Publication date: March 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Thomas E. Januario, David Shames
  • DIAGNOSTIC MARKERS
    Publication number: 20130084286
    Abstract: The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Application
    Filed: August 30, 2012
    Publication date: April 4, 2013
    Inventors: Thomas E. Januario, David Shames
  • SELECTING PATIENTS FOR THERAPY WITH A HER INHIBITOR
    Publication number: 20080317753
    Abstract: A method for selecting patients for therapy with a HER inhibitor, such as pertuzumab, based on gene expression analysis is described. A method for assessing HER phosphorylation or activation in a biological sample via gene expression analysis is also described.
    Type: Application
    Filed: May 1, 2008
    Publication date: December 25, 2008
    Applicant: GENENTECH, INC.
    Inventors: LUKAS C. AMLER, THOMAS E. JANUARIO